Q1:17 Biotechnology Deals Keep Climbing
Biotechnology deal activity has climbed steadily over the past five quarters. The sector reached 62 transactions in Q1:17, an increase of 13% over the previous quarter and up 94% year-over-year. The total is 31% of the 203 deals announced in the previous 12 months. M&A in this sector will remain active for years to come, as pharmaceutical companies that have abandoned their own R&D turn to buying up smaller biotechs with promising clinical-stage compounds. The 21st Century Cures Act also benefits this sector, with its billions of dollars in financing for both the “Cancer Moonshot” and the BRAIN Initiative. In the first quarter, 20 of the 62 transactions involved the purchase of an... Read More »Becton, Dickinson Leads the Medical Device Sector
The Medical Device sector isn’t seeing a flood of deals, but the dollars are adding up fast. In the first four months of 2017, dollars committed to deals in this sector have reached 60% of 2016’s total of $61.6 billion. With just 31 deals announced, deal volume stands at 27% of last year’s total of 112 transactions. Four deals have surpassed the $1 billion mark this year, and one currently accounts for 65% of this year’s $36.9 billion total. That deal, recently announced, is Becton, Dickinson and Company’s (NYSE: BDX) $24 billion purchase of C.R. Bard, Inc. (NYSE: BCR). In late April, Becton, Dickinson (BD) announced it would pay $317.00 per share for the New Jersey-based... Read More »Fresenius Injects $5.1 Billion into its U.S. Pharma Unit
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) has been a busy deal maker. In 2016, its subsidiary Fresenius Helios bought the Spanish hospital chain Quironsalud for $6.5 billion, its Renal Care division acquired the rights to a chronic kidney disease drug for up to $282 million, and then a German-based cardiovascular medical device company for an undisclosed price. The company also picked up dialysis clinics throughout India and New York State, and other drug licenses in the meantime. Now, it has turned its attention to strengthening Fresenius Kabi, its sterile injectable medicines subsidiary. Biosimilars are a fast-growing segment within the pharmaceutical market,... Read More »
Envision Rebrands Its Physician Services, and the Company
Envision Healthcare (NYSE: EVHC) officially merged with AmSurg Corp. (NYSE: AMSG) in December 2016. The $2.35 billion merger disappointed EVHC investors who were looking for a buyout by a larger company. But if they stick with EVHC, they may see some more trades soon. Envision Healthcare discussed its Q4:16 and full 2016 results on February 28, 2017. In the announcement, the now-combined company disclosed it was seeking to spin off either its medical transportation company, AMR, or its ambulatory surgery center division. Those are its smaller divisions, now that the merger is complete. The rebranded Envision Physicians Services accounted for 63% of the combined companies’ revenue of... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
